HFM
ZVRA icon

Hartford Financial Management’s Zevra Therapeutics ZVRA Stock Holding History

Hartford Financial Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-63
Closed -$7K – 426
2018
Q2 		$7K Buy
+63
New +$6.15K ﹤0.01% 346

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hartford Financial Management's ZVRA Position: Q3 2018 in Review

Hartford Financial Management sold out of Zevra Therapeutics (ZVRA) in Q3 2018, closing a stake of 63 shares — an estimated $7K sold.

Hartford Financial Management first reported a position in ZVRA in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2018.

  • Hartford Financial Management reported no remaining Zevra Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Hartford Financial Management sold 63 Zevra Therapeutics shares in Q3 2018, an estimated $7K.
  • Hartford Financial Management first reported a position in Zevra Therapeutics in Q2 2018 and held it in 1 quarter.
  • Hartford Financial Management's Zevra Therapeutics position peaked at $7K in Q2 2018.
  • 33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2018.

Based on Hartford Financial Management's 13F filing for Q3 2018, filed 1 Nov 2018.